A multi-country panel study linked sustained heat exposure to higher age-standardized adult physical inactivity, using a ...

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...

Patients with multiple sclerosis (MS) who were receiving disease-modifying therapies were found to have rare occurrences of ...

Vutrisiran kept a favorable safety profile in patients with transthyretin amyloidosis treated for up to 58 months, with AE ...

The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with ...

Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US. In 2009, Congress created a regulatory pathway for ...

Plan sponsors are able to dispute a PBM’s plan if it’s not reasonable or relevant, directly through CMS. Should PBMs refuse ...

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter ...

In an interview with the American Journal of Managed Care®, Greenspan explained why oxygen therapy is beneficial for patients ...

Cost-related delayed or forgone care was associated with 78% higher odds of an ED visit among Latino adults, indicating ...

Rebecca L. Siegel, MPH, lead author of the “Colorectal Cancer Statistics, 2026” report recently published in CA: A Cancer ...

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.